Drugs / REGN5093-M114
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04982224 | Nov 2021 → Oct 2025 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5093-M114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982224 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT04982224 ↗ |
| Target | MET | “REGN5093-M114 (METxMET Antibody-Drug Conjugate)” NCT04982224 ↗ |